Product news from the 02/06/07 news brief

Share this article:
GlaxoSmithKline said that the FDA has issued an approvable letter for its anti-clotting drug Arixtra (fondaparinux sodium). Glaxo is seeking approval to market the drug for use in treating unstable angina, or myocardial infarction. Arixtra is already approved for use during surgery in patients at risk for blood clots. Glaxo said in a statement that it would continue working with the FDA to provide the additional information requested to complete the assessment of Arixtra Global Arixtra sales totaled $44 million in 2005. Novo Nordisk received FDA approval for NovoLog (insulin aspart [rDNA origin] injection) for a pregnancy Category B rating, further validating the drug as a safe and effective treatment for pregnant women with Type 1 diabetes and their unborn children.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.